Related Experiment Video

Updated: May 3, 2026

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

7.4K

Prognostic polypeptide blood plasma biomarkers of Alzheimer's disease progression

Hongqian Yang1, Yaroslav Lyutvinskiy1, Sanna-Kaisa Herukka2

  • 1Division of Physiological Chemistry I, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.

Journal of Alzheimer'S Disease : JAD
|February 8, 2014
PubMed
Abstract

Insights

Blood protein biomarkers can predict Alzheimer's disease progression in mild cognitive impairment patients with 79% accuracy. Sex-specific models are crucial, as some biomarkers like alpha-2-macroglobulin differ between sexes.

Area of Science:

  • Neuroscience
  • Biomarker Discovery
  • Proteomics

Background:

  • Mild cognitive impairment (MCI) presents variable risks for progression to Alzheimer's disease (AD).
  • Accurate prediction of AD progression is vital for timely intervention.

Purpose of the Study:

  • To evaluate blood plasma polypeptide levels as predictors of AD progression in MCI patients.
  • To identify potential protein biomarkers for assessing AD risk.

Main Methods:

  • 119 MCI patient plasma samples analyzed using untargeted, label-free shotgun proteomics.
  • Multivariate analysis and cross-validation employed to select predictive biomarkers for progressive MCI.

Main Results:

  • A predictive model achieved approximately 79% accuracy in identifying progressive MCI.
  • Sex-specific protein biomarkers were identified, including alpha-2-macroglobulin (A2M), which showed a strong correlation with AD progression in females but not males.

Conclusions:

  • Sex bias in AD biomarkers necessitates sex-balanced cohorts or sex-specific models in research.
  • Blood protein biomarkers show promise for predicting AD progression in clinical settings.
Keywords:
Biomarkershuman blood plasmalabel-free quantificationmass spectrometry

More Related Videos

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets11:03

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets

Published on: February 10, 2020

7.9K
Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model06:02

Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model

Published on: July 26, 2011

37.8K

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
765
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K